Immediate Impact
45 standout
Citing Papers
Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Cyrus Khan being referenced
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
2022
ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
2021
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Cyrus Khan | 163 | 136 | 45 | 58 | 43 | 253 | |
| Wenbin Qian | 129 | 104 | 26 | 76 | 40 | 279 | |
| Sandra P. Susanibar-Adaniya | 161 | 126 | 50 | 114 | 27 | 301 | |
| Timothy Voorhees | 138 | 79 | 19 | 52 | 35 | 220 | |
| Meirav Kedmi | 124 | 144 | 50 | 47 | 31 | 269 | |
| Xin-lan Luo | 122 | 103 | 48 | 128 | 35 | 323 | |
| Praveen Ramakrishnan Geethakumari | 170 | 74 | 34 | 48 | 45 | 283 | |
| Megan M. Herr | 96 | 87 | 39 | 57 | 35 | 252 | |
| Ivana Ilić | 96 | 121 | 52 | 61 | 38 | 280 | |
| Ho Jong Jeon | 101 | 137 | 72 | 68 | 24 | 314 | |
| Ingrid Vášová | 177 | 216 | 65 | 23 | 39 | 328 |
All Works
Loading papers...